Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [10] - The company's lead product candidate, rezpegaldesleukin, is a first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one for atopic dermatitis and another for alopecia areata [10] Product Development - Rezpegaldesleukin is an interleukin-2 receptor (IL-2R) agonist that activates regulatory T cells (Tregs) and has shown promising dose-dependent clinical activity in treating moderate-to-severe atopic dermatitis [2][7] - The REZOLVE-AD Phase 2b study has completed target enrollment of 396 patients, with results expected in the second quarter of 2025 [3][4] - The primary endpoint of the study is the mean improvement in the Eczema Area and Severity Index (EASI) score after a 16-week induction treatment period [4] Clinical Trial Details - The REZOLVE-AD study enrolled patients who had not previously received biologic or JAK inhibitor therapies, with randomization across three different dose regimens of rezpegaldesleukin or placebo [3][5] - The trial was initiated in October 2023 and involved approximately 110 sites globally, with 67% of patients enrolled in European countries [5][6] - Enrollment criteria included a minimum EASI score of 16.0 and a minimum Body Surface Area (BSA) of 10% [6] Market Context - Atopic dermatitis affects approximately 30 million people in the United States, with less than 10% of patients currently receiving biologic treatments [3][9] - The company believes that novel mechanisms like rezpegaldesleukin are essential for addressing the needs of more patients suffering from this chronic skin disorder [3]
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis